MD ANDERSON CANCER CENTER announced a partnership with Hospital Israelita Albert Einstein in Brazil.
THE ASSOCIATION OF COMMUNITY CANCER CENTERS launched an online oncology drug database with information on drug coding, billing and reimbursement.
FDA and the European Medicines Agency both granted orphan drug designations to ABT-414, an investigational anti-epidermal growth factor receptor antibody drug conjugate developed by AbbVie. The compound is being evaluated for safety and efficacy in patients with glioblastoma multiforme.
ASTRAZENECA and Qiagen agreed to collaborate on the development of a liquid biopsy-based companion diagnostic to be paired with Iressa, AstraZeneca's targeted therapy for non-small cell lung cancer.
BRISTOL-MYERS SQUIBB formed an agreement with Leica Biosystems to develop companion diagnostic tests.
OPTIM ONCOLOGY and Urology Centers of Oklahoma, divisions of Oklahoma Multispecialty Group, have joined The US Oncology Network.
THE DR. SUSAN LOVE RESEARCH FOUNDATION received a nearly $1 million grant from the NIH to continue development of a portable self-reading ultrasound for breast screening.
MASSACHUSETTS GENERAL HOSPITAL received the American Hospital Association's inaugural Equity of Care Award for its efforts to reduce health care disparities and promote diversity within the organization's leadership and staff. The award was presented July 21 at the Health Forum-AHA Leadership Summit in San Diego.
JEFFREY ALBERS was named CEO of Blueprint Medicines.
THE CONQUER CANCER FOUNDATION of the American Society of Clinical Oncology named Raj Mantena and Aaron Sasson to its board of directors.
